FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to a method for predicting the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C. The essence of the method lies in the fact that a set of indicators of the level of alpha-fetoprotein, glypican-3 and ostepontin in venous blood is determined. The threshold value is pre-calculated for each tumor marker. The result is compared with the threshold values for alpha-fetoprotein (16.0 ng / ml); for osteopontin (80.0 ng / ml); for glypican-3 (1.0 ng / ml). The risk of developing the disease is predicted according to the following algorithm: if the level of three detectable tumor markers is less than or equal to the threshold value, there is no risk of developing hepatocellular carcinoma; if the threshold value of one of the tumor markers is exceeded, the risk of developing the disease is low; when the threshold value of two tumor markers is exceeded, the risk of developing the disease is high; when the threshold value of three detectable tumor markers is exceeded, the absolute risk of developing hepatocellular carcinoma is predicted.
EFFECT: use of the method allows predicting with high accuracy the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C.
1 cl, 1 dwg, 3 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING THE RISK OF HEPATOCELLULAR CARCINOMA IN THE PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2723891C1 |
METHOD FOR DIAGNOSING HEPATOCELLULAR CARCINOMA CASES | 2003 |
|
RU2319969C2 |
METHOD OF PREDICTING AN INCREASED RISK OF DECOMPENSATION OF LIVER CIRRHOSIS OR THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH LIVER CIRRHOSIS IN THE OUTCOME OF CHRONIC HEPATITIS C AFTER ACHIEVING A SUSTAINED VIROLOGIC RESPONSE | 2022 |
|
RU2800251C1 |
DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR HEPATIC GROWTHS DURING ULTRASOUND EXAMINATION | 2016 |
|
RU2632768C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF DIFFUSE AND FOCAL HEPATIC DISEASES | 2020 |
|
RU2771257C1 |
QUINONE THERAPEUTIC AGENT FOR TREATMENT OF LIVER DISEASE | 2003 |
|
RU2292875C2 |
METHOD FOR DIAGNOSING HEPATOCELLULAR CARCINOMA BY DETERMINING COEFFICIENT OF DEVELOPMENT OF HEPATOCELLULAR CARCINOMA BASED ON CHANGES IN T LEVELS OF MICRORNA EXPRESSION IN HUMAN BLOOD PLASMA AND SALIVA | 2020 |
|
RU2760937C1 |
METHOD FOR IDENTIFYING BIOLOGICAL MARKERS DETECTED IN HUMAN BIOLOGICAL MATERIALS IN VIEW OF POSSIBLE PRESENCE OF PATHOLOGICAL CONDITIONS OF THE HUMAN BODY, INCLUDING ONCOLOGICAL DISEASES, IMPLEMENTED BY MEANS OF MULTIPLEX IMMUNOENZYME SANDWICH IMMUNOASSAY | 2021 |
|
RU2779104C1 |
BIOMARKERS APPLICABLE FOR DIAGNOSING HEPATIC FIBROSIS | 2009 |
|
RU2505821C2 |
METHOD OF PROGNOSTIC ASSESSMENT OF DEVELOPMENT OF HEPATOCELLULAR CARCINOMA BASED ON DETERMINATION OF POLYMORPHISM OF HUMAN IFNAR-1 GENE AND A SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS | 2022 |
|
RU2811763C1 |
Authors
Dates
2021-06-04—Published
2020-08-10—Filed